Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. Its genome editing toolbox includes nuclease-based genome editing, base editors, RNA-mediated integration, including prime editing, and DNA-mediated integration, such CRISPR-associated transposases. The company has a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop and commercialize investigational medicines using genome editing technologies; and a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited TCR-based therapeutic products exclusively in the field of treatment, prevention, or diagnosis of any human cancer. Metagenomi, Inc. was incorporated in 2016 and is headquartered in Emeryville, California. Show more

Location: 5959 Horton Street, EmeryVille, CA, 94608, United States | Website: https://metagenomi.co | Industry: Biotechnology | Sector: Healthcare


Market Cap

56.7M

52 Wk Range

$1.23 - $4.92

Previous Close

$1.51

Open

$1.54

Volume

235,117

Day Range

$1.54 - $1.63

Enterprise Value

-85.76M

Cash

184.1M

Avg Qtr Burn

-22.91M

Insider Ownership

28.09%

Institutional Own.

17.90%

Qtr Updated

09/30/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date